The Obesity Epidemic in Mexico and the Need for Effective Treatments
Mexico faces a dual crisis of obesity and related health issues, threatening the sustainability of its healthcare system. As obesity rates continue to rise, there is an urgent need for effective treatment options. GLP-1 receptor agonists, such as semaglutide (Ozempic, Wegovy) and tirzepatida (Mounjaro, Zepbound), have shown promise in combating obesity. These medications, initially developed for type 2 diabetes, work by mimicking intestinal hormones that regulate appetite, glucose, and metabolism.
Clinical Efficacy of GLP-1 Agonists
Clinical studies have demonstrated significant weight loss with GLP-1 agonists. Semaglutide results in approximately 12% weight reduction, while tirzepatida achieves up to 16% loss in 68 weeks. Beyond aesthetics, these medications help reduce comorbidities such as hypertension, dyslipidemias, and cardiovascular risks, preventing heart attacks and hospitalizations.
Economic Considerations and Accessibility
Despite their effectiveness, the high cost of GLP-1 agonists poses a significant economic challenge. Monthly treatment costs range from 4,000 to 16,000 pesos in the private market, making them inaccessible for most Mexicans. In 2025, semaglutide was among the top 10 most expensive chronic therapies, with monthly costs potentially exceeding 20,000 pesos.
Government Perspective and Budget Constraints
The Mexican government has not committed to covering these treatments in public institutions due to budgetary constraints. Public health spending accounts for only 2.5% of the GDP, and with around 40 million adults affected by obesity, the annual cost of treating even a small fraction (10%) could surpass 20,000 million pesos.
Patent Expiration and the Promise of Generics
The good news is that patent expiration for early GLP-1 agonists, such as semaglutide, is imminent. This development could pave the way for more affordable generic versions. The US FDA has already approved oral generic versions in 2025, driving down prices through competition.
Balancing Costs and Benefits
While GLP-1 agonists offer hope in the fight against obesity, their high costs and limited accessibility could exacerbate fiscal burdens without proper budgetary policies. Mexico must carefully evaluate the true impact of these medications through cost-effectiveness assessments by institutions like CENETEC. By viewing these drugs as long-term investments rather than expenses, Mexico can better manage chronic conditions and their associated costs.
Key Questions and Answers
- What are GLP-1 agonists? GLP-1 agonists are medications initially developed for type 2 diabetes that mimic intestinal hormones regulating appetite, glucose, and metabolism. They have shown promise in treating obesity.
- Why are GLP-1 agonists expensive in Mexico? High costs stem from limited public coverage, with monthly treatment ranging from 4,000 to 16,000 pesos. This makes them inaccessible for most Mexicans.
- When will generic versions of GLP-1 agonists be available? Patent expiration for early GLP-1 agonists, like semaglutide, is imminent. The US FDA has already approved oral generic versions, which could drive down prices through competition.
- How can Mexico balance costs and benefits of GLP-1 agonists? By evaluating cost-effectiveness and viewing these medications as long-term investments rather than expenses, Mexico can better manage chronic conditions and their associated costs.
